Study To Assess Long Term Safety Of Pazopanib

Completed · Phase 1

Conditions studied: Carcinoma, Renal Cell

In brief

This study was a rollover study to evaluate the long term safety of pazopanib and to continue to provide pazopanib to patients who participated in a GSK sponsored pazopanib study until pazopanib is available commercially.

Key facts

Study ID

NCT00387205

Run by

Novartis Pharmaceuticals

People needed

188

Starts

2006-06-20

Expected to finish

2018-03-08

Last updated by the study team

2019-03-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Novartis Investigative Site — Duarte, California, United States
• Novartis Investigative Site — Santa Monica, California, United States
• Novartis Investigative Site — Aurora, Colorado, United States
• Novartis Investigative Site — Indianapolis, Indiana, United States
• Novartis Investigative Site — Detroit, Michigan, United States
• Novartis Investigative Site — Minneapolis, Minnesota, United States
• Novartis Investigative Site — Lebanon, New Hampshire, United States
• Novartis Investigative Site — New Brunswick, New Jersey, United States
• Novartis Investigative Site — Buffalo, New York, United States
• Novartis Investigative Site — Durham, North Carolina, United States
• Novartis Investigative Site — Cleveland, Ohio, United States
• Novartis Investigative Site — Greenville, South Carolina, United States
• Novartis Investigative Site — Nashville, Tennessee, United States
• Novartis Investigative Site — Houston, Texas, United States
• Novartis Investigative Site — Tacoma, Washington, United States
• Novartis Investigative Site — Lyon, France
• Novartis Investigative Site — Singapore, Singapore
• Novartis Investigative Site — Sutton, Surrey, United Kingdom
• Novartis Investigative Site — Newcastle upon Tyne, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.